MBOT
Microbot Medical Inc.
$1.80
-1.10%
$122.2M
No data for this timeframe.
Vol
Market Cap$122.2M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders7 funds
Inst. Value$7.0M
Inst. Activity3 buys / 2 sells
Reddit Sentiment44° Neutral
SEC Reports10
Press Releases1
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0000883975·Prev Close $1.82
Recent Activity
Jun 9, 2026
SEC
Microbot Medical announced its first Midwest account, a healthcare system in Michigan, for its LIBERTY Endovascular Robo
8-K — Impact 4/10
Jun 9, 2026
other
Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System
Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® E
Jun 2, 2026
SEC
Microbot Medical announced its first North Carolina-based healthcare system customer for the LIBERTY Endovascular Roboti
8-K — Impact 4/10
May 26, 2026
SEC
Microbot Medical announced it received regulatory approval from the Israeli Ministry of Health's AMAR Division to market
8-K — Impact 6/10
Apr 1, 2026
Insider
Wilson David James sold 10,000 shares
Director @ $0.00 ($0.00)
Apr 1, 2026
Insider
Wenderow Tal Baruch sold 10,000 shares
Director @ $0.00 ($0.00)
Apr 1, 2026
Insider
Laxminarain Prattipati sold 10,000 shares
Director @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — ADD
3,329,721 shares ($6.7M)
Price Targets
$7.00
+288.9% upside
Strong Buy
Current $1.80
Low $4.00
Median $5.00
High $12.00
3 analysts
$4.00
$12.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 3, 2026 | LUCID CAPITAL MARKETS | INITIATE | Buy |
| Apr 14, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 10, 2026 | B. Riley Securities | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.08 ▼ -4.2% | $-0.09 — $-0.08 | 17% YoY | 3 |
| Next Q | $-0.08 | $-0.08 — $-0.08 | -14% YoY | 3 |
| Current FY | $-0.30 ▲ +6.3% | $-0.31 — $-0.29 | -3% YoY | 2 |
| Next FY | $-0.32 ▲ +3.0% | $-0.36 — $-0.28 | -7% YoY | 2 |
Latest Reports
NEUTRAL
8-K
4/10
Microbot Medical announced its first Midwest account, a healthcare system in Michigan, for its LIBERTY Endovascular Robo
Jun 9, 2026
NEUTRAL
8-K
4/10
Microbot Medical announced its first North Carolina-based healthcare system customer for the LIBERTY Endovascular Roboti
Jun 2, 2026
NEUTRAL
Press
5/10
Microbot Medical announced the publication of its ACCESS-PVI multicenter feasibility study in the Journal of Vascular an
Mar 24, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $6.7M | ADD |
| MORGAN STANLEY | $137.9K | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $122.2K | NEW |
| RENAISSANCE TECHNOLOGIES LLC | $49.1K | NEW |
| WELLS FARGO & COMPANY/MN | $17.5K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 1, 2026 | Wilson David | A | $0.00 |
| Apr 1, 2026 | Wenderow Tal | A | $0.00 |
| Apr 1, 2026 | Laxminarain Prattipati | A | $0.00 |
| Apr 1, 2026 | Madden Martin | A | $0.00 |
| Apr 1, 2026 | Burell Scott | A | $0.00 |
Reddit Sentiment
44°
Neutral
Bearish
Neutral
Bullish
7 institutional holders with $7.0M total value (3,497,326 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, TWO. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,329,721 | $6.7M | 95.2% | ADD +42.1% |
| 2 | MORGAN STANLEY | 68,972 | $137.9K | 2.0% | DOUBLED +779.4% |
| 3 | TWO SIGMA INVESTMENTS, LP | 61,098 | $122.2K | 1.7% | NEW |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 24,560 | $49.1K | 0.7% | NEW |
| 5 | WELLS FARGO & COMPANY/MN | 8,735 | $17.5K | 0.2% | TRIM -58.6% |
| 6 | BANK OF AMERICA CORP /DE/ | 4,239 | $8.5K | 0.1% | NEAR_EXIT -81.7% |
| 7 | FMR LLC | 1 | $2.00 | 0.0% | NEAR_EXIT -99.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 2,343,561 | 3,329,721 | +42.1% | $6.7M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 7,843 | 68,972 | +779.4% | $137.9K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 24,560 | — | $49.1K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 23,152 | 4,239 | -81.7% | $8.5K | 2025-Q4 |
| FMR LLC | NEAR_EXIT | 311 | 1 | -99.7% | $2.00 | 2025-Q4 |
| UBS Group AG | DOUBLED | 41,528 | 202,845 | +388.5% | $618.7K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 5,867 | 23,152 | +294.6% | $70.6K | 2025-Q3 |
| MORGAN STANLEY | NEAR_EXIT | 157,770 | 7,843 | -95.0% | $23.9K | 2025-Q3 |
| FMR LLC | DOUBLED | 1 | 311 | +31000.0% | $948.00 | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 741,165 | 2,050,638 | +176.7% | $5.2M | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 21,013 | 157,770 | +650.8% | $397.6K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 477 | 5,867 | +1130.0% | $14.8K | 2025-Q2 |
| FMR LLC | NEAR_EXIT | 7 | 1 | -85.7% | $3.00 | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 459,549 | 741,165 | +61.3% | $1.1M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 68,198 | — | $103.0K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 53,900 | — | $81.4K | 2025-Q1 |
| UBS Group AG | DOUBLED | 1,074 | 41,136 | +3730.2% | $62.1K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 1,012 | 21,013 | +1976.4% | $31.7K | 2025-Q1 |
| FMR LLC | DOUBLED | 1 | 7 | +600.0% | $11.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 105,658 | 0 | -100.0% | $0.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 105,658 | — | $118.3K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 21,418 | 8,876 | -58.6% | $9.9K | 2024-Q4 |
| UBS Group AG | NEAR_EXIT | 44,503 | 1,074 | -97.6% | $1.2K | 2024-Q4 |
10 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Wilson David James | Director | A | 10,000 | $0.00 | $0.00 |
| Apr 1, 2026 | Wenderow Tal Baruch | Director | A | 10,000 | $0.00 | $0.00 |
| Apr 1, 2026 | Laxminarain Prattipati | Director | A | 10,000 | $0.00 | $0.00 |
| Apr 1, 2026 | Madden Martin J. | Director | A | 10,000 | $0.00 | $0.00 |
| Apr 1, 2026 | Burell Scott R | Director | A | 10,000 | $0.00 | $0.00 |
| Apr 1, 2026 | Stockburger Aileen Ptucha | Director | A | 10,000 | $0.00 | $0.00 |
| Feb 18, 2026 | Gadot Harel | Chairman, President and CEO | A | 480,000 | $0.00 | $0.00 |
| Feb 18, 2026 | Diaz-Cartelle Juan | Chief Medical Officer | A | 105,000 | $0.00 | $0.00 |
| Feb 18, 2026 | Sharon Simon | General Manager, CTO | A | 105,000 | $0.00 | $0.00 |
| Feb 18, 2026 | Vaknin Rachel | Chief Financial Officer | A | 105,000 | $0.00 | $0.00 |
10 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 7 neutral. Avg impact: 4.4/10.
NEUTRAL
8-K
4/10
Microbot Medical announced its first Midwest account, a healthcare system in Michigan, for its LIBER
Jun 9, 2026
NEUTRAL
8-K
4/10
Microbot Medical announced its first North Carolina-based healthcare system customer for the LIBERTY
Jun 2, 2026
BULLISH
8-K
6/10
Microbot Medical announced it received regulatory approval from the Israeli Ministry of Health's AMA
May 26, 2026
NEUTRAL
8-K
4/10
Microbot Medical filed an 8-K announcing a conference call on May 18, 2026, to address what it calls
May 15, 2026
BULLISH
8-K
5/10
Microbot Medical announced that it recorded revenue from its limited market release (LMR) of the LIB
May 14, 2026
NEUTRAL
8-K
3/10
Microbot Medical announced initial commercial adoption of its LIBERTY Endovascular Robotic System fo
May 5, 2026
NEUTRAL
8-K
3/10
Microbot Medical announced that updated occupational safety guidelines from SIR and CIRSE highlight
Apr 22, 2026
NEUTRAL
8-K
5/10
Microbot Medical announced the full market release of its LIBERTY Endovascular Robotic System and wi
Apr 14, 2026
BULLISH
8-K
7/10
Microbot Medical announced the successful limited market release and commencement of full market rel
Apr 13, 2026
NEUTRAL
8-K
3/10
Microbot Medical Inc. (MBOT) filed an 8-K to disclose compensation adjustments for three executive o
Feb 24, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.00 mean target
+288.9% upside
Strong Buy (1.00)
$4.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $1.80 |
| Target Low | $4.00 |
| Target Mean | $7.00 |
| Target Median | $5.00 |
| Target High | $12.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.08 | $-0.09 | $-0.08 | 16.7% | -4.2% | — | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.08 | $-0.08 | $-0.08 | -14.3% | +0.0% | — | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-0.30 | $-0.31 | $-0.29 | -3.5% | +6.3% | — | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-0.32 | $-0.36 | $-0.28 | -6.7% | +3.0% | 1↑ 0↓ | $0.0B | 207.2% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.083 | |
| 7d ago | $-0.090 | +0.007 |
| 30d ago | $-0.080 | -0.003 |
| 60d ago | $-0.080 | -0.003 |
| 90d ago | $-0.087 | +0.003 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 3, 2026 | LUCID CAPITAL MARKETS | INITIATE | — | Buy |
| Apr 14, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 10, 2026 | B. Riley Securities | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
44°
Neutral
Bearish
Neutral
Bullish
4 mentions
1 bullish
2 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 14, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 13, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 24, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
$MBOT 10Q - Q1
▲ 1
💬 1
⚡ 0.5
MBOT adopted by top tier Florida Hospital
▲ 17
💬 6
⚡ 0.5
Jun 9, 2026
other
Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System
Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System
Jun 2, 2026
short_volume
Short Volume: MBOT — 58.0% short (0.4M / 0.8M)
Short: 436,704 | Exempt: 20,684 | TRF Vol: 753,269 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: MBOT — 61.8% short (0.5M / 0.8M)
Short: 482,594 | Exempt: 12,061 | TRF Vol: 780,332 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: MBOT — 55.6% short (1.0M / 1.7M)
Short: 962,638 | Exempt: 3,498 | TRF Vol: 1,730,827 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: MBOT — 60.3% short (0.4M / 0.7M)
Short: 439,090 | Exempt: 8 | TRF Vol: 727,689 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: MBOT — 55.2% short (0.5M / 1.0M)
Short: 541,565 | Exempt: 70,848 | TRF Vol: 981,766 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings_calendar
MBOT Q1 2026 Earnings Scheduled — 2026-05-12
May 6, 2026
short_volume
Short Volume: MBOT — 56.1% short (0.4M / 0.7M)
Short: 399,036 | Exempt: 5 | TRF Vol: 710,934 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
May 1, 2026
short_volume
Short Volume: MBOT — 64.5% short (0.3M / 0.5M)
Short: 349,281 | Exempt: 235 | TRF Vol: 541,721 | Short Ratio: 64.5% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
other
Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)
Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in EMEA
Apr 27, 2026
short_volume
Short Volume: MBOT — 58.5% short (0.4M / 0.6M)
Short: 359,867 | Exempt: 200 | TRF Vol: 615,160 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
other
Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®
Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®
Apr 22, 2026
short_volume
Short Volume: MBOT — 60.5% short (0.5M / 0.9M)
Short: 526,497 | Exempt: 1,493 | TRF Vol: 870,744 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
short_volume
Short Volume: MBOT — 62.7% short (0.7M / 1.1M)
Short: 683,131 | Exempt: 125 | TRF Vol: 1,088,688 | Short Ratio: 62.7% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
short_volume
Short Volume: MBOT — 56.7% short (0.6M / 1.0M)
Short: 580,159 | Exempt: 725 | TRF Vol: 1,023,014 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)